Company intelligence / Profile preview

Xiamen Longjin Biotechnology

Xiamen, Fujian, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

Xiamen Longjin Biotechnology is a Chinese biotech company focused on products and services related to pathological diagnosis. In February 2024, Jiuqiang Biotech’s subsidiary Maixin Biotech acquired a 25.21% stake in the company, aiming for strong business synergy and rapid revenue growth by leveraging existing customer resources and distribution channels. The partnership positions Xiamen Longjin Biotechnology as strategically important for expanding product pipelines in diagnostic technologies.

Modalities: Diagnostic reagentsBiologicsSmall molecules
Industry: Pathology

Partnerships

Jiuqiang Biotech / Maixin BiotechSinopharm investments

Beyond the preview

Go deeper on Xiamen Longjin Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiamen Longjin Biotechnology.

Explore the full profile